Related Experiment Video
Updated: Aug 23, 2025
08:40
Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
8.7K
Hypermethylation of Long Non-Coding RNA Genes Group in the Breast Cancer Development and Progression
A D Selezneva1, E A Filippova2, A D Selezneva1
1Faculty of Biology, M. V. Lomonosov Moscow State University, Moscow, Russia.
Bulletin of Experimental Biology and Medicine
|November 2, 2022
Summary
Increased methylation of three long non-coding RNA (lncRNA) genes, MEG3, ZNF667-AS1, and SEMA3B-AS1, was observed in breast cancer. These lncRNAs show potential as diagnostic and prognostic markers for breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Long non-coding RNAs (lncRNAs) play crucial roles in cellular processes.
- Aberrant gene methylation is implicated in cancer development.
- Specific lncRNAs are being investigated as potential cancer biomarkers.
Purpose of the Study:
- To investigate the methylation status of four lncRNA genes (MEG3, ZNF667-AS1, GAS5, SEMA3B-AS1) in breast cancer.
- To assess the correlation between lncRNA methylation and clinical parameters of breast cancer.
- To identify novel lncRNA-based biomarkers for breast cancer diagnosis and prognosis.
Main Methods:
- Quantitative methylation-specific PCR was used for methylation analysis.
- Analysis was performed on 38 paired (tumor/normal) breast cancer samples.
- Correlations with cancer stage, metastasis, and tumor size were evaluated.
Main Results:
- Significantly increased methylation (p<0.001) was detected in MEG3, ZNF667-AS1, and SEMA3B-AS1.
- Methylation levels of all studied lncRNAs correlated with cancer stage and lymph node metastasis.
- MEG3 and ZNF667-AS1 methylation also correlated with tumor size.
- Methylation of ZNF667-AS1 and SEMA3B-AS1 in breast cancer was reported for the first time.
Conclusions:
- The study identified MEG3, ZNF667-AS1, and SEMA3B-AS1 as frequently methylated lncRNAs in breast cancer.
- These lncRNAs demonstrate significant correlations with key clinical features, including cancer stage and metastasis.
- The findings suggest that these lncRNAs hold promise as novel diagnostic and prognostic biomarkers for breast cancer.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
01:46Epigenetic Regulation
31.3K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.3K
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K